Login:
 
Chemotherapy with hormone therapy boosts survival in advanced prostate cancer. Practitioner 2016;260 (1791):8

Chemotherapy with hormone therapy boosts survival in advanced prostate cancer

21 Mar 2016Registered users

The addition of docetaxel at the time of hormone therapy initiation for advanced prostate cancer improved overall survival by 10 months, in a large  randomised controlled trial. The STAMPEDE study commenced in 2005, and has recruited men with metastatic, high-risk localised or node-positive prostate cancer who were newly diagnosed or had high-risk recurrence following previous local therapy. STAMPEDE utilises a multi-arm approach to test whether addition of other agents at the time of hormone therapy initiation improves overall survival.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article